扶正化瘀膠囊聯(lián)合核苷類抗病毒藥物治療乙肝肝硬化失代償期患者的臨床效果

打開文本圖片集

[Abstract] Objective：To evaluate the therapeutic effect of Fuzheng Huayu Capsules combined with nucleoside antiviral drugs in patients with decompensated hepatitis Bcirrhosis，and to analyze its influence on liver function，liver fibrosis and immune function indicators.Method： This study was prospective.Atotal of 102 patients with decompensated hepatitis Bcirrhosis admitted to People's Hospital of Ruijin City from October 2022 to March 2O24 were divided into the study group （n=51）and the conventional group （n=51） byusing the random number table method. The study group received Fuzheng Huayu Capsules + nucleoside antiviral drugs treatment， and the conventional group receivedonly nucleoside antiviral drugs treatment.Both groups were treated continuously for24 weeks.Theclinical efficacy，andTCMsyndromesscores，liver stiffnessmeasurement （LSM），liverfunction indicators，liver fibrosis indicators，and Tcellsubgroup indicators beforeand after treatment were observed and compared between the two groups.Result： The overall clinical efective rate in the study group （86.27 % ） was higher than in the conventional group （68.63 % ）（ P <0.05）.After treatment， the scores of TCM syndromes （hypochondriac pain，hypochondriac mas，dimcomplexion，thirst withoutdesire todrink，fatigue），andthelevelsofLSM，TBI，AST， ALT， procollagen type || peptide （PIIP）， type IV collagen （ IV -C），laminin （LN），hyaluronic acid （HA），and CD8 + in the study group were lower than those inthe conventional group，the levels of albumin （ALB），cholinesterase （ChE）， CD3 3+ ，CD 4+ ，and CD4+/CD8+ were higher than those in the conventional group （ P <0.05）. Conclusion： Fuzheng Huayu Capsules combined with nucleoside antiviral drugs can significantly improve the clinical symptoms，liver function，liver fibrosis，and immune function of patients with decompensated hepatitis Bcirrhosis.

[Keywords] Fuzheng Huayu CapsulesNucleoside antiviral drugsHepatitis B Cirrhosis Decompensated stage

乙型肝炎肝硬化失代償期是慢性乙型肝炎發(fā)展至肝功能衰竭的終末階段，患者通常伴有嚴(yán)重的肝功能異常、肝纖維化進(jìn)展及免疫功能障礙，預(yù)后不良且病情復(fù)雜，對(duì)生活質(zhì)量和生存率有顯著負(fù)面影響[]。（剩余6367字）